Breast cancer vaccines: maximizing cancer treatment by tapping into host immunity

被引:66
作者
Emens, LA [1 ]
Reilly, RT [1 ]
Jaffee, EM [1 ]
机构
[1] Johns Hopkins Univ, Sch Med, Dept Oncol, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA
关键词
D O I
10.1677/erc.1.00671
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Optimizing standard treatment modalities for breast cancer has improved the outlook for women afflicted with it, but the fact that 40% still ultimately die from the disease highlights the need for new therapies. Remarkable advances in molecular immunology and biotechnology have created a unique opportunity for developing active vaccination strategies that engage the patient's own immune system in the fight against breast cancer. Early clinical trials have established the safety and bioactivity of some breast cancer vaccine approaches, with a hint of clinical response. They have also highlighted the importance of elucidating the pharmacodynamic interactions between established therapies for breast cancer, such as tamoxifen, aromatase inhibitors, chemotherapy, the HER-2/neu-specific monoclonal antibody trastuzumab (Herceptin), and breast cancer vaccines. Preclinical studies have simultaneously defined the importance of developing targeted approaches for circumventing established immune tolerance to breast cancer during the vaccination process. The first strategies targeting the negative influence of CD4(+)CD25(+)T regulatory cells and the CTLA-4 signaling pathway are just entering clinical testing in combination with tumor vaccines. Developing the most potent approach for activating antitumor immunity while maintaining the efficacy of standard approaches to breast cancer management will ensure that active immunotherapy is successfully integrated into the standard of care.
引用
收藏
页码:1 / 17
页数:17
相关论文
共 115 条
[71]  
Miles David, 2003, Clin Breast Cancer, V3 Suppl 4, pS134, DOI 10.3816/CBC.2003.s.002
[72]   A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer [J].
Miles, DW ;
Towlson, KE ;
Graham, R ;
Reddish, M ;
Longenecker, BM ;
TaylorPapadimitriou, J ;
Rubens, RD .
BRITISH JOURNAL OF CANCER, 1996, 74 (08) :1292-1296
[73]  
Murray JL, 2002, CLIN CANCER RES, V8, P3407
[74]   Reevaluation of the cellular immune response in breast cancer patients vaccinated with MUC1 [J].
Musselli, C ;
Ragupathi, G ;
Gilewski, T ;
Panageas, KS ;
Spinat, Y ;
Livingston, PO .
INTERNATIONAL JOURNAL OF CANCER, 2002, 97 (05) :660-667
[75]   Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer [J].
Nemunaitis, J ;
Sterman, D ;
Jablons, D ;
Smith, JW ;
Fox, B ;
Maples, P ;
Hamilton, S ;
Borellini, F ;
Lin, A ;
Morali, S ;
Hege, K .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (04) :326-331
[76]  
Nigam A, 1998, INT J ONCOL, V12, P161
[77]   Regulatory T cells and mechanisms of immune system control [J].
O'Garra, A ;
Vieira, P .
NATURE MEDICINE, 2004, 10 (08) :801-805
[78]   Spinning molecular immunology into successful immunotherapy [J].
Pardoll, DM .
NATURE REVIEWS IMMUNOLOGY, 2002, 2 (04) :227-238
[79]   Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma [J].
Phan, GQ ;
Yang, JC ;
Sherry, RM ;
Hwu, P ;
Topalian, SL ;
Schwartzentruber, DJ ;
Restifo, NP ;
Haworth, LR ;
Seipp, CA ;
Freezer, LJ ;
Morton, KE ;
Mavroukakis, SA ;
Duray, PH ;
Steinberg, SM ;
Allison, JP ;
Davis, TA ;
Rosenberg, SA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (14) :8372-8377
[80]   Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin E2 secretion in patients with breast cancer [J].
Pockaj, BA ;
Basu, GD ;
Pathangey, LB ;
Gray, RJ ;
Hernandez, JL ;
Gendler, SJ ;
Mukherjee, P .
ANNALS OF SURGICAL ONCOLOGY, 2004, 11 (03) :328-339